Search

Author/Creator Nijland, M.

1. P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE. (23rd June 2022)

Authors:
Belada, D.; Leppä, S.; Wahlin, B. E.; Nijland, M.; Christensen, J. H.; de Vos, S.; Holte, H.; Linton, K. M.; Abbas, A.; Wang, L.; Dinh, M.; Elliott, B.; Falchi, L.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1025
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY. (23rd June 2022)

Authors:
Doorduijn, J.; Issa, S.; van der Holt, B.; Minnema, M.; Seute, T.; Durian, M.; Cull, G.; van der Poel, M.; Stevens, W.; Zijlstra, J.; Nijland, M.; Mason, K.; Beeker, A.; Brandsma, D.; van den Bent, M.; Gonzalez, M.; de Jong, D.; Bromberg, J.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1062
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P1209: INCIDENCE, TREATMENT AND OUTCOME OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA: A POPULATION-BASED COHORT STUDY IN THE NETHERLANDS. (23rd June 2022)

Authors:
Meeuwes, F. O.; Brink, M.; Van der Poel, M. W.; Kersten, M. J.; Wondergem, M. J.; Mutsaers, P. G.; Böhmer, L. H.; Woei-A-Jin, F. J. S. H.; Visser, O.; Oostvogels, R.; Jansen, P. M.; Plattel, W. J.; Huls, G. A.; Vermaat, J. S.; Nijland, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1095
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P1215: PRELIMINARY PHASE 1/2 RESULTS OF SUBCUTANEOUS EPCORITAMAB + R-DHAX/C IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT. (23rd June 2022)

Authors:
Cordoba, R.; Falchi, L.; Phillips, T.; de Vos, S.; Nijland, M.; Offner, F.; Bykhovski, I.; Wu, J.; Wang, L.; Rana, A.; Abrisqueta, P.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1101
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P1254: RESPONSE TO DA-EPOCH-R IN PATIENTS WITH HIGH GRADE B CELL LYMPHOMA IS ASSOCIATED WITH A REDUCTION OF PD1 POSITIVE EXHAUSTED CD8 T CELLS. (23rd June 2022)

Authors:
de Jonge, V.; Duetz, C.; Bruins, W.; van Werkhoven, E.; Nijland, M.; de Heer, K.; van der Poel, M.; Sandberg, Y.; Klerk, C.; de Jong, D.; Zijlstra, J.; Kersten, M. J.; Mutis, T.; Chamuleau, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1139
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis. (December 2018)

Authors:
Montes de Jesus, F.M.; Kwee, T.C.; Nijland, M.; Kahle, X.U.; Huls, G.; Dierckx, R.A.J.O.; van Meerten, T.; Gheysens, O.; Dierickx, D.; Vergote, V.; Noordzij, W.; Glaudemans, A.W.J.M.
Journal:
Critical reviews in oncology/hematology
Issue:
Volume 132(2018)
Page Start:
27
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. PROTEOMICS MARKERS PROGNOSTIC FOR OUTCOME OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER TREATMENT: RESULTS FROM THE HOVON‐109 STUDY. (12th June 2019)

Authors:
van der Straten, L.; Hosnijeh, F.; van der Straten, L.; Kater, A.P.; van Oers, M.H.; Posthuma, W.F.; Chamuleau, M.E.; Nijland, M.; Hoogendoorn, M.; De Croon, F.; Wittebol, S.; Kerst, J.; Marijt, E.W.; Raymakers, R.A.; Koene, H.R.; Dobber, J.A.; Tonino, S.H.; Kersting, S.S.; Langerak, A.W.; Levin, M.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
208
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. RITUXIMAB MAINTENANCE FOR PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA IN FIRST COMPLETE REMISSION: RESULTS FROM A RANDOMIZED HOVON‐NORDIC LYMPHOMA GROUP PHASE III STUDY. (12th June 2019)

Authors:
Lugtenburg, P.; de Nully Brown, P.; van der Holt, B.; d'Amore, F.; Koene, H.; de Jongh, E.; Fijnheer, R.; Loosveld, O.; Böhmer, L.; Pruijt, H.; Verhoef, G.; Hoogendoorn, M.; Bilgin, Y.; Nijland, M.; Lam, K.; de Keizer, B.; de Jong, D.; Zijlstra, J.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
79
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗